Literature DB >> 22949931

Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6.

Vikas Mehta1, Kevin Rycyna, Bart M M Baesens, Güliz A Barkan, Gladell P Paner, Robert C Flanigan, Eva M Wojcik, Girish Venkataraman.   

Abstract

BACKGROUND: Biopsy Gleason score (bGS) remains an important prognostic indicator for adverse outcomes in Prostate Cancer (PCA). In the light of recent studies purporting difference in prognostic outcomes for the subgroups of GS7 group (primary Gleason pattern 4 vs. 3), upgrading of a bGS of 6 to a GS≥7 has serious implications. We sought to identify pre-operative factors associated with upgrading in a cohort of GS6 patients who underwent prostatectomy.
DESIGN: We identified 281 cases of GS6 PCA on biopsy with subsequent prostatectomies. Using data on pre-operative variables (age, PSA, biopsy pathology parameters), logistic regression models (LRM) were developed to identify factors that could be used to predict upgrading to GS≥7 on subsequent prostatectomy. A decision tree (DT) was constructed.
RESULTS: 92 of 281 cases (32.7%) were upgraded on subsequent prostatectomy. LRM identified a model with two variables with statistically significant ability to predict upgrading, including pre-biopsy PSA (Odds Ratio 8.66; 2.03-37.49, 95% CI) and highest percentage of cancer at any single biopsy site (Odds Ratio 1.03, 1.01-1.05, 95% CI). This two-parameter model yielded an area under curve of 0.67. The decision tree was constructed using only 3 leave nodes; with a test set classification accuracy of 70%.
CONCLUSIONS: A simplistic model using clinical and biopsy data is able to predict the likelihood of upgrading of GS with an acceptable level of certainty. External validation of these findings along with development of a nomogram will aid in better stratifying the cohort of low risk patients as based on the GS.

Entities:  

Keywords:  Carcinoma; binary recursive partitioning; prostate/pathology/predictive modeling; statistical techniques/logistic regression

Mesh:

Substances:

Year:  2012        PMID: 22949931      PMCID: PMC3430101     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  24 in total

1.  Prostate biopsy volume indices do not predict for significant Gleason upgrading.

Authors:  Christopher R King; Deep A Patel; Martha K Terris
Journal:  Am J Clin Oncol       Date:  2005-04       Impact factor: 2.339

2.  Clinical predictors of upgrading to Gleason grade 4 or 5 disease at radical prostatectomy: potential implications for patient selection for radiation and androgen suppression therapy.

Authors:  A V D'Amico; A A Renshaw; L Arsenault; D Schultz; J P Richie
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-11-01       Impact factor: 7.038

3.  Natural history of progression after PSA elevation following radical prostatectomy.

Authors:  C R Pound; A W Partin; M A Eisenberger; D W Chan; J D Pearson; P C Walsh
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

4.  Prostate biopsy grading errors: a sampling problem?

Authors:  C R King; J P Long
Journal:  Int J Cancer       Date:  2000-12-20       Impact factor: 7.396

5.  Patterns of prostate cancer biopsy grading: trends and clinical implications.

Authors:  C R King
Journal:  Int J Cancer       Date:  2000-12-20       Impact factor: 7.396

6.  Predictors for clinically relevant Gleason score upgrade in patients undergoing radical prostatectomy.

Authors:  Christian Thomas; Karin Pfirrmann; Frauke Pieles; Alexander Bogumil; Rolf Gillitzer; Christoph Wiesner; Joachim W Thüroff; Sebastian W Melchior
Journal:  BJU Int       Date:  2011-05-18       Impact factor: 5.588

7.  Extended prostate biopsy scheme improves reliability of Gleason grading: implications for radiotherapy patients.

Authors:  Christopher R King; John E McNeal; Harcharan Gill; Joseph C Presti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-06-01       Impact factor: 7.038

8.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer.

Authors:  A V D'Amico; R Whittington; S B Malkowicz; D Schultz; M Schnall; J E Tomaszewski; A Wein
Journal:  J Urol       Date:  1995-07       Impact factor: 7.450

9.  Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE).

Authors:  Matthew R Cooperberg; Deborah P Lubeck; Shilpa S Mehta; Peter R Carroll
Journal:  J Urol       Date:  2003-12       Impact factor: 7.450

10.  Accuracy of transrectal ultrasound guided prostate biopsy: histopathological correlation to matched prostatectomy specimens.

Authors:  Kamil Cam; Selcuk Yucel; Levent Turkeri; Atif Akdas
Journal:  Int J Urol       Date:  2002-05       Impact factor: 3.369

View more
  3 in total

1.  Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.

Authors:  Xueming Wu; Guanping Yu; Daniel Lindner; Susann M Brady-Kalnay; Qi Zhang; Zheng-Rong Lu
Journal:  Am J Nucl Med Mol Imaging       Date:  2014-07-15

2.  Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature.

Authors:  Farzana A Faisal; Debasish Sundi; Phillip M Pierorazio; Mark W Ball; Elizabeth B Humphreys; Misop Han; Jonathan I Epstein; Alan W Partin; H Ballentine Carter; Trinity J Bivalacqua; Edward M Schaeffer; Ashley E Ross
Journal:  BJU Int       Date:  2014-08-13       Impact factor: 5.588

3.  Exploration on Gleason score variation trend of patients with prostate carcinoma from 1996 to 2019: a retrospective single center study.

Authors:  Weiyu Zhang; Gongwei Wang; Fengling Lan; Huanrui Wang; Danhua Shen; Kexin Xu; Tao Xu; Hao Hu
Journal:  Gland Surg       Date:  2021-02
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.